Sermorelin held FDA approval as Geref, in both a diagnostic and a paediatric treatment form. Both are discontinued and no sermorelin product is currently marketed in the United States. Current use is compounded or research-grade.
The short answer
Sermorelin's benefit is the least speculative in this whole category, because a regulator once agreed it had one. Sermorelin is GHRH(1-29) — the first 29 amino acids of the body's own growth hormone-releasing hormone, which is the part that carries the activity, with a plasma half-life of about 10 to 20 minutes in humans (Esposito et al., Adv Drug Deliv Rev 2003). It raises the body's own GH, and in children with growth hormone deficiency it grew them. It also lost, commercially and clinically, to injecting growth hormone directly — which is why it is no longer on the market and why its modern reputation as an "anti-aging" peptide has no approval behind it.
The approval, and exactly what it covered
Two Geref products existed, and the distinction matters:
Geref, NDA 019863 — approved 28 December 1990, supplied as 0.05 mg per ampoule; the diagnostic formulation, used as a GHRH stimulation test (Drugs@FDA, NDA 019863).
Geref, NDA 020443 — approved 26 September 1997 with orphan designation, supplied as 0.5 mg and 1 mg vials; the treatment formulation (Drugs@FDA, NDA 020443).
The treatment indication was narrow. FDA's own 2024 summary notes that among growth hormone secretagogues, "only sermorelin (Geref, NDA 020443) was approved for the treatment of short stature associated with GHD in pediatric patients" — and the approval covered a preselected subpopulation with idiopathic GH deficiency who first passed a Geref stimulation test, with the label directing that "children who do not adequately respond (i.e., peak GH level < 2 ng/mL) should be excluded from Geref therapy" (FDA briefing document, PCAC October 2024).
That exclusion criterion is the whole logic of a secretagogue in one sentence. The drug asks the pituitary to release growth hormone. If the pituitary cannot, the drug does nothing — which is why no product in this class has ever been approved for adults with growth hormone deficiency.
Why it was discontinued
Both Geref products are recorded in Drugs@FDA as discontinued, each carrying a Federal Register determination that the product "was not discontinued or withdrawn for safety or effectiveness reasons" — the specific regulatory finding that separates a commercial withdrawal from a safety withdrawal. A review written shortly afterwards put it plainly: sermorelin "could not compete with rhGH and was withdrawn as a therapeutic entity by the manufacturer" (Walker, Clin Interv Aging 2006).
The head-to-head numbers show why. In nine prepubertal children with radiation-induced GH deficiency, GHRH(1-29)-NH2 at 15 µg/kg twice daily by subcutaneous injection raised height velocity from 3.3 cm/year before treatment to 6.0 cm/year over a year (p = 0.004) — a real effect. When the same children were switched to growth hormone for the following year, height velocity reached 7.5 cm/year (Ogilvy-Stuart et al., Clin Endocrinol 1997). Twice-daily injections for a smaller effect than a competitor product is not a safety problem. It is a losing position in a market.
What happened when it was tried in older adults
The "anti-aging" positioning traces to a specific line of research, and the findings are more mixed than the marketing. Nineteen healthy adults aged 55 to 71 (ten women, nine men) received a closely related GHRH(1-29) analogue — [Nle27]GHRH-(1-29)-NH2 — at 10 µg/kg nightly for 16 weeks after a four-week saline run-in (Khorram et al., J Clin Endocrinol Metab 1997):
- IGF-1 rose significantly within two weeks.
- Skin thickness increased in both sexes.
- Lean body mass increased in men only.
- Insulin sensitivity improved in men but not women; fasting glucose and insulin were unchanged.
- Well-being and libido improved in men; sleep was unaffected in both groups.
The authors concluded the treatment had "anabolic effects favoring men more than women." Two caveats belong with that. The molecule tested carries a norleucine substitution at position 27 and is not identical to sermorelin. And the finding most often claimed for sermorelin in wellness marketing — better sleep — is the one this study explicitly did not find.
How it compares to related peptides
CJC-1295 without DAC — the same 29-residue backbone with four amino-acid substitutions intended to resist enzymatic breakdown. No published human study.
CJC-1295 with DAC — the same backbone again, plus an albumin-binding group that stretches the half-life from minutes to days.
Tesamorelin — the GHRH analogue that is still approved, with phase 3 visceral-fat data in HIV lipodystrophy.
Ipamorelin and the GHRPs — a different receptor entirely (ghrelin/GHS-R1a), which is why they are combined with sermorelin rather than substituted for it.
Sermorelin is prohibited in sport at all times under WADA section S2 as a growth hormone-releasing factor (WADA Prohibited List).
See also sermorelin side effects and dosing education.